Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin
Castle Biosciences (Nasdaq: CSTL) has announced its sponsorship of the 71st Annual Montagna Symposium on the Biology of the Skin, scheduled for Oct. 17-21, 2024, in Stevenson, Washington. The event, hosted by the Oregon Health & Science University Department of Dermatology, aims to bring together clinicians and scientists to explore focused aspects of dermatology and skin biology.
Dr. Matthew Goldberg, SVP of medical at Castle Biosciences, expressed pride in supporting the symposium's mission to exchange knowledge and integrate recent discoveries into clinical practice. The Montagna Symposium, established in 1950, has attracted over 5,000 attendees and serves as a platform for new concepts in cutaneous biology.
This year's symposium will focus on skin of color dermatology, covering topics such as genetics, social determinants of health, and cutaneous disorders affecting people with pigmented skin. Dr. Tamia Harris-Tryon, the symposium program chair, highlighted the importance of support from organizations like Castle Biosciences in challenging disease management paradigms for improved patient care.
Castle Biosciences (Nasdaq: CSTL) ha annunciato il suo patrocinio per il 71° Simposio Annuale Montagna sulla Biologia della Pelle, in programma dal 17 al 21 ottobre 2024 a Stevenson, Washington. L'evento, organizzato dal Dipartimento di Dermatologia della Oregon Health & Science University, ha l'obiettivo di riunire clinici e scienziati per esplorare aspetti specifici della dermatologia e della biologia della pelle.
Il Dr. Matthew Goldberg, SVP medico di Castle Biosciences, ha espresso il suo orgoglio nel sostenere la missione del simposio di scambiare conoscenze e integrare le recenti scoperte nella pratica clinica. Il Simposio Montagna, fondato nel 1950, ha attratto oltre 5.000 partecipanti e funge da piattaforma per nuovi concetti nella biologia cutanea.
Il simposio di quest'anno si concentrerà sulla dermatologia della pelle di colore, trattando temi come genetica, determinanti sociali della salute e disturbi cutanei che colpiscono le persone con pelle pigmentata. La Dr.ssa Tamia Harris-Tryon, presidente del programma del simposio, ha sottolineato l'importanza del supporto da parte di organizzazioni come Castle Biosciences nel mettere in discussione i paradigmi di gestione delle malattie per un miglioramento dell'assistenza ai pazienti.
Castle Biosciences (Nasdaq: CSTL) ha anunciado su patrocinio para el 71º Simposio Anual Montagna sobre la Biología de la Piel, programado del 17 al 21 de octubre de 2024 en Stevenson, Washington. El evento, organizado por el Departamento de Dermatología de la Oregon Health & Science University, tiene como objetivo reunir a clínicos y científicos para explorar aspectos específicos de la dermatología y la biología de la piel.
El Dr. Matthew Goldberg, SVP médico de Castle Biosciences, expresó su orgullo por apoyar la misión del simposio de intercambiar conocimientos e integrar los recientes descubrimientos en la práctica clínica. El Simposio Montagna, establecido en 1950, ha atraído a más de 5,000 asistentes y sirve como plataforma para nuevos conceptos en biología cutánea.
El simposio de este año se centrará en la dermatología de la piel de color, abarcando temas como genética, determinantes sociales de la salud y trastornos cutáneos que afectan a personas con piel pigmentada. La Dra. Tamia Harris-Tryon, presidenta del programa del simposio, subrayó la importancia del apoyo de organizaciones como Castle Biosciences en desafiar los paradigmas de gestión de enfermedades para mejorar la atención al paciente.
캐슬 바이오사이언스(Castle Biosciences, Nasdaq: CSTL)는 2024년 10월 17일부터 21일까지 워싱턴주 스티븐슨에서 열리는 제71회 몬타냐 피부 생물학 심포지엄의 후원을 발표했습니다. 이 행사는 오레곤 건강 및 과학대학교 피부과에서 주최하며, 피부과 및 피부 생물학의 특정 측면을 탐구하기 위해 임상의와 과학자들을 모으는 것을 목표로 하고 있습니다.
Castle Biosciences의 의학 부사장인 매튜 골드버그 박사는 심포지엄의 사명을 지원하게 되어 자부심을 느낀다고 밝혔으며, 지식을 교환하고 최근 발견을 임상 실습에 통합하는 것의 중요성을 강조했습니다. 1950년에 설립된 몬타냐 심포지엄은 5,000명 이상의 참석자를 끌어 모았으며, 피부 생물학의 새로운 개념을 위한 플랫폼 역할을 하고 있습니다.
올해 심포지엄은 유색 피부의 피부과에 초점을 맞추며, 유전학, 건강의 사회적 결정 요인, 색소가 있는 피부를 가진 사람들에게 영향을 미치는 피부 질환과 같은 주제를 다룰 것입니다. 심포지엄 프로그램 의장인 타미아 해리스-트라이온 박사는 Castle Biosciences와 같은 조직의 지원이 환자 치료 개선을 위한 질병 관리 패러다임에 도전하는 것의 중요성을 강조했습니다.
Castle Biosciences (Nasdaq: CSTL) a annoncé son parrainage pour le 71e Symposium Annuel Montagna sur la Biologie de la Peau, prévu du 17 au 21 octobre 2024 à Stevenson, Washington. L'événement, organisé par le Département de Dermatologie de l'Oregon Health & Science University, vise à rassembler des cliniciens et des scientifiques pour explorer des aspects ciblés de la dermatologie et de la biologie de la peau.
Le Dr. Matthew Goldberg, SVP médical chez Castle Biosciences, a exprimé sa fierté de soutenir la mission du symposium d'échanger des connaissances et d'intégrer les découvertes récentes dans la pratique clinique. Le Symposium Montagna, créé en 1950, a attiré plus de 5 000 participants et sert de plateforme pour de nouveaux concepts en biologie cutanée.
Le symposium de cette année se concentrera sur la dermatologie de la peau colorée, abordant des sujets tels que la génétique, les déterminants sociaux de la santé et les troubles cutanés affectant les personnes à peau pigmentée. Le Dr. Tamia Harris-Tryon, présidente du programme du symposium, a souligné l'importance du soutien d'organisations comme Castle Biosciences dans la remise en question des paradigmes de gestion des maladies pour améliorer les soins aux patients.
Castle Biosciences (Nasdaq: CSTL) hat seine Unterstützung für das 71. jährliche Montagna-Symposium zur Biologie der Haut bekannt gegeben, welches vom 17. bis 21. Oktober 2024 in Stevenson, Washington, stattfinden wird. Die Veranstaltung, die vom Dermatologischen Institut der Oregon Health & Science University ausgerichtet wird, hat das Ziel, Klinikern und Wissenschaftlern zusammenzubringen, um fokussierte Aspekte der Dermatologie und Hautbiologie zu erkunden.
Dr. Matthew Goldberg, SVP für medizinische Belange bei Castle Biosciences, äußerte Stolz darüber, die Mission des Symposiums, Wissen auszutauschen und aktuelle Entdeckungen in die klinische Praxis zu integrieren, unterstützen zu dürfen. Das Montagna-Symposium, das 1950 ins Leben gerufen wurde, hat mehr als 5.000 Teilnehmer angezogen und dient als Plattform für neue Konzepte in der kutanen Biologie.
In diesem Jahr wird sich das Symposium auf die Dermatologie der Hautfarbe konzentrieren und Themen wie Genetik, soziale Determinanten der Gesundheit und kutane Erkrankungen, die Menschen mit pigmentierter Haut betreffen, behandeln. Dr. Tamia Harris-Tryon, Programmvorsitzende des Symposiums, betonte die Bedeutung der Unterstützung durch Organisationen wie Castle Biosciences bei der Herausforderung der Paradigmen des Krankheitsmanagements zur Verbesserung der Patientenversorgung.
- Castle Biosciences is sponsoring a prestigious dermatology symposium, potentially enhancing its reputation in the field
- The company's involvement may lead to new collaborations and insights in dermatological research
- None.
“Castle is proud to support the Montagna Symposium and their multi-faceted mission,” said Matthew Goldberg, M.D., senior vice president, medical, at Castle Biosciences. “We hope that bringing together clinicians and scientists of varied backgrounds to thoroughly investigate focused aspects of dermatology and skin biology will allow for the exchange of knowledge and recent discoveries to move dermatological research toward integration into clinical practice.”
Since its establishment in 1950, the Montagna Symposium has attracted more than 5,000 scientists, physicians and student attendees to its annual meetings, seeking to further frontiers and bridge gaps within the study of cutaneous biology and the skin. The unique event provides a proving ground for new concepts to share with the greater scientific and medical communities and aims to foster mentorship and collaboration by forging connections and inspiring the next generation of dermatologic experts.
“This year’s symposium will focus on skin of color dermatology and touch on genetics, social determinants of health, and disparities and cutaneous disorders that disproportionately affect people with pigmented skin,” said Tamia Harris-Tryon, M.D., Ph.D., symposium program chair. “We are pleased for the continued support of organizations like Castle Biosciences who make our event possible and share our commitment to challenging disease management paradigms for the betterment of patient care.”
More information about this year’s symposium can be found at montagnasymposium.org.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241011680320/en/
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
When and where is Castle Biosciences (CSTL) sponsoring the 71st Annual Montagna Symposium?
What is the focus of the 2024 Montagna Symposium supported by Castle Biosciences (CSTL)?
How many attendees has the Montagna Symposium attracted since its establishment in 1950?
Who is the program chair for the 2024 Montagna Symposium sponsored by Castle Biosciences (CSTL)?
